

## Quarterly Activities Report and Appendix 4C

Bio-Gene Technology Limited (**ASX:BGT, Bio-Gene or the Company**), an Australian agtech company developing the next generation of novel insecticides derived from nature, provides an update on activities for the quarter ended 31 March 2026 (Q3 FY26).

### Q3 FY26 Highlights

- **Two key Flavocide® registration enabling studies are currently underway: the rat acute neurotoxicity study (OECD 424) and rat reproductive toxicity study (OECD 443) , with preliminary reports expected May and September 2026 respectively.**
- **Flavocide regulatory program is on track, targeting a first APVMA registration submission in Australia in March 2027, to be followed in future by submissions in the USA and other major markets.**
- **Non-binding term sheet signed with Sumitomo Corporation and Nakashima Trading Co. to develop and market insecticide products containing Qcide® in Japan's US\$1B household pest market, targeting a late 2026 launch.**
- **15th Qcide harvest successfully completed at the far north Queensland plantation, with newly planted areas expected to be ready for initial harvest in Spring 2026.**

### Flavocide Regulatory Development Updates:

#### **Flavocide extended one-generation reproductive toxicity study in rats (OECD 443) underway**

An extended one-generation reproductive toxicity study (OECD 443) for Flavocide is underway and this study forms a core element of Bio-Gene's Flavocide active ingredient registration data package for Australia and other international jurisdictions. Successful completion of this study will be a key milestone in advancing Flavocide toward registration and commercialisation, initially in public health and consumer markets.

The results will inform key aspects of Bio-Gene's dossier of mammalian toxicology data to be submitted to the Australian Pesticides & Veterinary Medicines Authority (APVMA) in support of its application for the registration of Flavocide as an active constituent for use in products for the control of insect pests. As the study is being conducted in accordance with OECD Test Guideline 443 and Good Laboratory Practice (GLP) standards, the data generated will be suitable for submission to regulatory bodies operating under the OECD's Mutual Acceptance of Data (MAD) framework. This includes OECD member countries such as Australia, New Zealand, the USA, Canada, Japan, the United Kingdom and many European countries, as well as non-member countries that are full adherents to the OECD MAD framework, including South Africa, Singapore, India, Brazil, Argentina, Malaysia and Thailand.

The OECD 443 study is designed to evaluate potential reproductive and developmental effects in rats following prenatal and postnatal exposure to Flavocide and to evaluate systemic toxicity in parental animals and their offspring, including pregnant and lactating females. Flavocide will be administered to adult male and female rats in the diet before and after mating and to females during pregnancy and lactation. Offspring will be monitored from birth through weaning, with a subset continuing on the treated diet into adulthood to assess growth and general health over time, including targeted examinations of reproductive organs and other key tissues.

The dose range-finding study (DRF Study), which determined the doses to be included in the main study, has been completed. The in-life phase of the main OECD 443 study is expected to finish during July 2026, with the preliminary report scheduled to be received during September 2026 and the final report during November 2026.

The OECD 443 study is one of several core toxicity studies required to be included in the Flavocide regulatory dossier. It builds on shorter-term mammalian toxicology work in rats and other test species already completed by Bio-Gene, such as acute and sub-chronic toxicity tests and complements other ongoing and planned long-term toxicity studies.

#### **Flavocide acute neurotoxicity study underway (OECD 424)**

Bio-Gene also announced that an acute Flavocide neurotoxicity study (OECD 424) is underway. This is a key study required to generate essential safety data for inclusion in the Flavocide regulatory dossier and to support subsequent commercialisation of Flavocide. The study is designed to assess whether Flavocide has any effect on the neurological health of rats.

These results will also contribute to Bio-Gene's dossier of mammalian toxicology data to be submitted to the APVMA. Conducted in accordance with OECD Test Guideline 424 and Good Laboratory Practice (GLP) standards, this data will also be accepted by regulatory bodies operating under the OECD's MAD framework, covering the major target countries mentioned above.

This study evaluates any potential neurotoxicity effects in adult rats following oral exposure to Flavocide, including any changes in neuro-behaviour and neuropathology. The study will establish a robust toxicological profile critical for human health risk assessments and labelling of Flavocide products. The study is being conducted by a Contract Research Organisation (CRO) in accordance with OECD guidelines and GLP.

The dose range-finding arm of the study (DRF Study) has been completed. The in-life phase of the main OECD 424 study is expected to conclude during April 2026, with the preliminary report scheduled for May 2026 and the final report during June 2026.

### **Progress in regulatory development of Flavocide and first regulatory submission timeline**

In March 2026, Bio-Gene provided an update on the overall regulatory development of Flavocide, confirming that its development program and toxicology studies are progressing well. Results from the two completed studies, the 28-day rat repeat dose oral toxicity study (OECD 407) and the pilot in-vivo metabolism and pharmacokinetics study (OECD 417 part 1), have supported progression into the major reproductive toxicity (OECD 443) and acute neurotoxicity (OECD 424) studies. The remaining studies, comprising a rat 90-day oral repeat dose study (OECD 408), a GLP in-vivo metabolism and pharmacokinetics study (OECD 417 part 2), a rabbit prenatal GLP developmental toxicology study (OECD 414) and a dog 14-day oral repeat dose study (OECD 409), are planned to run concurrently with overlapping timelines.

Based on progress to date, Bio-Gene is currently targeting submission of its first application for registration of Flavocide as a new active constituent with the APVMA in March 2027<sup>1</sup>, with subsequent applications for registration in the USA and other major territories planned. The first application will aim to support product approvals for the use of Flavocide for professional and domestic use and including public health use patterns for mosquito control and potentially other flying insects. Formulated product registrations would be pursued separately by Bio-Gene's commercial partners.

Bio-Gene is also undertaking a 5-batch analysis of Flavocide technical material to characterise its product composition and impurity profile, with this work in the final stages of completion. A GLP accelerated storage stability study is also planned and an ambient real-time storage stability study is planned to commence shortly to confirm the long-term stability of the Flavocide technical material and support the APVMA dossier and future global registrations.

#### **Qcide Development Updates:**

##### **Qcide Japan partnership with Sumitomo Corporation and Nakashima Trading Co.**

In March, Bio-Gene signed a non-binding term sheet with Sumitomo Corporation (Sumitomo) and Nakashima Trading Co. Ltd (Nakashima) to develop and market a range of insecticide products containing Qcide for Japan's household nuisance insect pest market<sup>2</sup>, targeting launch in late 2026. Definitive binding agreements are expected to be signed during May 2026.

Under the terms of the planned transaction, Bio-Gene will produce Qcide oil in Queensland for supply to Nakashima via Sumitomo, and will license relevant intellectual property for use by both parties in Japan. Sumitomo will coordinate the ordering, trade financing, transportation and approval for the importation of Qcide into Japan. Nakashima will undertake evaluation of prototype formulations, arrange further efficacy testing against insect species of interest in Japan and then

---

<sup>1</sup> This estimate is subject to a range of factors, including continued availability of planned study slots scheduled with Contract Research Organisations (CROs) and achievement of planned study start dates, QA release, data review, study report finalisation and availability of capital required for completion of these studies and other business operations.

<sup>2</sup> The term 'household nuisance insect pests' refers to domestic or peri-domestic pests targeted for amenity or comfort (including, for example, biting or stinging or nuisance or uncleanliness) and may include wood pests such as termites. This category excludes agricultural or any crop uses and any public health or disease prevention claims.

formulate, package, promote and supply the Qcide-containing product range to consumers via home improvement centres, pharmacies, supermarkets and online e-commerce channels.

The home insecticide market in Japan is currently estimated at US\$1B in sales annually<sup>3</sup>. While synthetic insecticides currently dominate with around 68.5% market share, the market for natural insecticides has been growing rapidly, driven by a shift in consumer preferences toward products that are safer, eco-friendly and more convenient. Household nuisance insect pest products in Japan — targeting pests such as ants, flies, stink bugs and spiders in domestic settings — may be supplied to consumers without a formal government registration process, provided claims are appropriately constrained to nuisance pests rather than crop protection or disease-vector-prevention uses.

### **15<sup>th</sup> Qcide Harvest Completed**

During the first calendar quarter of 2026, the Company successfully completed its 15<sup>th</sup> harvest and extraction of Qcide oil at its plantation site in far north Queensland. The harvest has further validated Qcide oil production under standardised operations and processing conditions, with the oil produced to a consistent commercial specification.

Bio-Gene continues to optimise the efficiency of oil extraction from biomass using pre-treatment techniques and equipment modifications to the steam distillation process, with the objective of maximising Qcide oil recovery from each tonne of biomass and ensuring the oil is produced at the lowest possible cost as the program expands for large-scale commercial production and supply to partners.

The tree improvement and selection program has been expanded and is producing superior trees to support further scale-up of Qcide oil production. A newly planted area is now well established, with more advanced sections expected to be ready for initial harvest in Spring 2026. To meet potential market demand, preparation for further seedling production is also underway to support re-stocking and expansion of the current plantation area. The seed production area is now in flower, marking further progress in the tree improvement program.

### **Corporate Activities**

#### **Virtual Healthcare Conference Presentation**

In March, Bio-Gene CEO & Managing Director Tim Grogan presented a Company update at the NWR Communications Virtual Healthcare Conference. Shareholders, investors and interested parties can view a replay of the presentation by [visiting this link](#).

#### **Appointment of Chief Financial Officer & Company Secretary**

During the first calendar quarter of 2026, the Company announced the appointment of Mr Drew Speedy as Chief Financial Officer (CFO) and Company Secretary. Mr Speedy is a Certified Practising Accountant and member of the Governance Institute of Australia with more than 20 years' experience in senior finance and company secretarial roles across ASX listed and private companies.

---

<sup>3</sup> Japan Home Insecticides Market Forecast 2022 – 2028, Inkwood Research (2021)

He is the founder and Director of DTS Corporate Pty Ltd, which provides CFO and company secretarial services to ASX listed and private entities.

### **Financials**

Payments to related parties, comprising compensation in the form of salary and superannuation paid to executive and non-executive directors, were \$190,689 for the first calendar quarter of 2026.

Approved for release on ASX by Bio-Gene Board of Directors.

- ENDS -

### **For further information, please contact:**

Bio-Gene Technology Limited:  
E: [bgt.info@bio-gene.com.au](mailto:bgt.info@bio-gene.com.au)

Matthew Wright  
NWR Communications  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)  
M: 0451 896 420

---

### **About Bio-Gene Technology Limited**

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance. Its unique products are based on a naturally occurring class of compounds proven to overcome insecticide resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across crop protection, grain storage, public health and consumer uses. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

[www.bio-gene.com.au](http://www.bio-gene.com.au)

Flavocide® and Qcide® are registered trademarks of Bio-Gene Technology Limited.

## Appendix 4C

Quarterly cash flow report for entities  
subject to Listing Rule 4.7B

## Name of entity

Bio-Gen Technology Limited

## ABN

32 071 735 950

## Quarter ended ("current quarter")

31 March 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 Months) \$A'000
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	128	503
1.2 Payments for		
(a) commercialisation expenses	(82)	(334)
(b) research and development	(190)	(1,319)
(c) intellectual property	(63)	(166)
(d) professional services	(45)	(74)
(e) directors' expenses	(47)	(140)
(f) administration and corporate costs	(113)	(363)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	5	20
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (R&D Refund)	-	520
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(407)</b>	<b>(1,353)</b>

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

<b>2.</b>	<b>Cash flows from investing activities</b>		
2.1	Payments to acquire or for:	-	-
	(a) entities		
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:	-	-
	(a) entities		
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	-	-

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	965
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(25)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	(51)
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (share proceeds received in advance)		
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	-	<b>889</b>

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	1,081	1,138
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(407)	(1,353)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	889
4.5	Effect of movement in exchange rates on cash held	-	-
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>674</b>	<b>674</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	124	80
5.2	Call deposits	550	701
5.3	Bank overdrafts	-	-
5.4	Other (Term Deposits)	-	300
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>674</b>	<b>1,081</b>

<b>6.</b>	<b>Payments to related parties of the entity and their associates</b>	<b>Current quarter \$A'000</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1	191
6.2	Aggregate amount of payments to related parties and their associates included in item 2	N/A

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*

Note 6.1: Director's fees paid to Directors or their related entities plus remuneration paid to Executive Directors.

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

7. <b>Financing facilities</b>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	N/A	N/A
7.2 Credit standby arrangements	N/A	N/A
7.3 Other (please specify)	N/A	N/A
7.4 <b>Total financing facilities</b>	<b>N/A</b>	<b>N/A</b>
7.5 <b>Unused financing facilities available at quarter end</b>	<b>N/A</b>	
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. <b>Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	(407)
8.2 Cash and cash equivalents at quarter end (item 4.6)	674
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	<b>674</b>
8.5 <b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	1.66
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer:	Yes
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer:	Yes, the Company is currently in the advanced stages of planning to undertake a capital raising. The Company believes these capital raise activities will be successfully based on discussions with advisors.
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer:	Yes, based on the discussions with advisors and history of undertaking successful capital raises to fund operations.
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

**Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 27 April 2026

Authorised by: The Board of Directors

(Name of body or officer authorising release – see note 4)

**Notes**

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.
6. Net movements in GST are included in this item.
7. Prior Quarter Corrections. Immaterial minor errors and reallocations of expenses from previous quarter reports are corrected on a year-to-date basis. Movements disclosed for the current quarter have been correctly calculated.